Bühring KU, Sailer H, Faro HP, Leopold G, Pabst J, Garbe A (1986). "Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans". Journal of Cardiovascular Pharmacology. 8 (Suppl 11): S21 –S28. doi:10.1097/00005344-198511001-00004. PMID2439794. S2CID38147937.
Horikiri Y, Suzuki T, Mizobe M (March 1998). "Pharmacokinetics and metabolism of bisoprolol enantiomers in humans". Journal of Pharmaceutical Sciences. 87 (3): 289–294. doi:10.1021/js970316d. PMID9523980.
CIBIS-II Investigators (January 1999). "The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial". The Lancet. 353 (9146): 9–13. doi:10.1016/S0140-6736(98)11181-9. S2CID10083527.>
Leopold G, Pabst J, Ungethüm W, Bühring KU (1986). "Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist". Journal of Clinical Pharmacology. 26 (8): 616–621. doi:10.1002/j.1552-4604.1986.tb02959.x. PMID2878941. S2CID42159046.
Kaumann AJ, Lemoine H (October 1985). "Direct labelling of myocardial beta 1-adrenoceptors. Comparison of binding affinity of 3H-(-)-bisoprolol with its blocking potency". Naunyn-Schmiedeberg's Archives of Pharmacology. 331 (1): 27–39. doi:10.1007/bf00498849. PMID2866449. S2CID22328991.
Schliep HJ, Schulze E, Harting J, Haeusler G (April 1986). "Antagonistic effects of bisoprolol on several beta-adrenoceptor-mediated actions in anaesthetized cats". European Journal of Pharmacology. 123 (2): 253–261. doi:10.1016/0014-2999(86)90666-7. PMID3011461.
Smith C, Teitler M (April 1999). "Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors". Cardiovascular Drugs and Therapy. 13 (2): 123–126. doi:10.1023/A:1007784109255. PMID10372227. S2CID12639448.
Wellstein A, Palm D, Belz GG (1986). "Affinity and selectivity of beta-adrenoceptor antagonists in vitro". Journal of Cardiovascular Pharmacology. 8 (Suppl 11): S36 –S40. doi:10.1097/00005344-198511001-00006. PMID2439796. S2CID30987576.
Bundkirchen A, Brixius K, Bölck B, Nguyen Q, Schwinger RH (January 2003). "Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies". European Journal of Pharmacology. 460 (1): 19–26. doi:10.1016/S0014-2999(02)02875-3. PMID12535855.
Nuttall SL, Routledge HC, Kendall MJ (June 2003). "A comparison of the beta1-selectivity of three beta1-selective beta-blockers". Journal of Clinical Pharmacy and Therapeutics. 28 (3): 179–186. doi:10.1046/j.1365-2710.2003.00477.x. PMID12795776. S2CID58760796.
Kirch W, Rose I, Demers HG, Leopold G, Pabst J, Ohnhaus EE (August 1987). "Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease". Clinical Pharmacokinetics. 13 (2): 110–117. doi:10.2165/00003088-198713020-00003. PMID2887325. S2CID25105692.
Cvan Trobec K, Grabnar I, Kerec Kos M, Vovk T, Trontelj J, Anker SD, et al. (July 2016). "Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study". European Journal of Clinical Pharmacology. 72 (7): 813–822. doi:10.1007/s00228-016-2041-1. PMID26996442. S2CID14146663.
drugbank.com
go.drugbank.com
"Bisoprolol". go.drugbank.com. Archived from the original on 17 August 2022. Retrieved 17 August 2022.
drugs.com
"Bisoprolol Fumarate". The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.
World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
Bühring KU, Sailer H, Faro HP, Leopold G, Pabst J, Garbe A (1986). "Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans". Journal of Cardiovascular Pharmacology. 8 (Suppl 11): S21 –S28. doi:10.1097/00005344-198511001-00004. PMID2439794. S2CID38147937.
Horikiri Y, Suzuki T, Mizobe M (March 1998). "Pharmacokinetics and metabolism of bisoprolol enantiomers in humans". Journal of Pharmaceutical Sciences. 87 (3): 289–294. doi:10.1021/js970316d. PMID9523980.
Leopold G, Pabst J, Ungethüm W, Bühring KU (1986). "Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist". Journal of Clinical Pharmacology. 26 (8): 616–621. doi:10.1002/j.1552-4604.1986.tb02959.x. PMID2878941. S2CID42159046.
Bennett MR, Chang CL, Tuffery C, Hopping S, Hancox RJ (March 2021). "The impact of regular bisoprolol on the response to salbutamol in asthma: A double-blind randomized placebo-controlled crossover trial". Respirology. 26 (3): 225–232. doi:10.1111/resp.13955. PMID33043552. S2CID222301890.
Bristow MR, Hershberger RE, Port JD, Minobe W, Rasmussen R (March 1989). "Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium". Molecular Pharmacology. 35 (3): 295–303. PMID2564629.
Haeusler G, Schliep HJ, Schelling P, Becker KH, Klockow M, Minck KO, et al. (1986). "High beta 1-selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol". Journal of Cardiovascular Pharmacology. 8 (Suppl 11): S2-15. doi:10.1097/00005344-198511001-00002. PMID2439793. S2CID24617470.
Harting J, Becker KH, Bergmann R, Bourgois R, Enenkel HJ, Fuchs A, et al. (February 1986). "Pharmacodynamic profile of the selective beta 1-adrenoceptor antagonist bisoprolol". Arzneimittel-Forschung. 36 (2): 200–208. PMID2870720.
Kaumann AJ, Lemoine H (October 1985). "Direct labelling of myocardial beta 1-adrenoceptors. Comparison of binding affinity of 3H-(-)-bisoprolol with its blocking potency". Naunyn-Schmiedeberg's Archives of Pharmacology. 331 (1): 27–39. doi:10.1007/bf00498849. PMID2866449. S2CID22328991.
Klockow M, Greiner HE, Haase A, Schmitges CJ, Seyfried C (February 1986). "Studies on the receptor profile of bisoprolol". Arzneimittel-Forschung. 36 (2): 197–200. PMID2870719.
Schliep HJ, Schulze E, Harting J, Haeusler G (April 1986). "Antagonistic effects of bisoprolol on several beta-adrenoceptor-mediated actions in anaesthetized cats". European Journal of Pharmacology. 123 (2): 253–261. doi:10.1016/0014-2999(86)90666-7. PMID3011461.
Smith C, Teitler M (April 1999). "Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors". Cardiovascular Drugs and Therapy. 13 (2): 123–126. doi:10.1023/A:1007784109255. PMID10372227. S2CID12639448.
Wellstein A, Palm D, Belz GG (1986). "Affinity and selectivity of beta-adrenoceptor antagonists in vitro". Journal of Cardiovascular Pharmacology. 8 (Suppl 11): S36 –S40. doi:10.1097/00005344-198511001-00006. PMID2439796. S2CID30987576.
Bundkirchen A, Brixius K, Bölck B, Nguyen Q, Schwinger RH (January 2003). "Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies". European Journal of Pharmacology. 460 (1): 19–26. doi:10.1016/S0014-2999(02)02875-3. PMID12535855.
Nuttall SL, Routledge HC, Kendall MJ (June 2003). "A comparison of the beta1-selectivity of three beta1-selective beta-blockers". Journal of Clinical Pharmacy and Therapeutics. 28 (3): 179–186. doi:10.1046/j.1365-2710.2003.00477.x. PMID12795776. S2CID58760796.
Kirch W, Rose I, Demers HG, Leopold G, Pabst J, Ohnhaus EE (August 1987). "Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease". Clinical Pharmacokinetics. 13 (2): 110–117. doi:10.2165/00003088-198713020-00003. PMID2887325. S2CID25105692.
Cvan Trobec K, Grabnar I, Kerec Kos M, Vovk T, Trontelj J, Anker SD, et al. (July 2016). "Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study". European Journal of Clinical Pharmacology. 72 (7): 813–822. doi:10.1007/s00228-016-2041-1. PMID26996442. S2CID14146663.
Bühring KU, Sailer H, Faro HP, Leopold G, Pabst J, Garbe A (1986). "Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans". Journal of Cardiovascular Pharmacology. 8 (Suppl 11): S21 –S28. doi:10.1097/00005344-198511001-00004. PMID2439794. S2CID38147937.
CIBIS-II Investigators (January 1999). "The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial". The Lancet. 353 (9146): 9–13. doi:10.1016/S0140-6736(98)11181-9. S2CID10083527.>
Leopold G, Pabst J, Ungethüm W, Bühring KU (1986). "Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist". Journal of Clinical Pharmacology. 26 (8): 616–621. doi:10.1002/j.1552-4604.1986.tb02959.x. PMID2878941. S2CID42159046.
Bennett MR, Chang CL, Tuffery C, Hopping S, Hancox RJ (March 2021). "The impact of regular bisoprolol on the response to salbutamol in asthma: A double-blind randomized placebo-controlled crossover trial". Respirology. 26 (3): 225–232. doi:10.1111/resp.13955. PMID33043552. S2CID222301890.
Haeusler G, Schliep HJ, Schelling P, Becker KH, Klockow M, Minck KO, et al. (1986). "High beta 1-selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol". Journal of Cardiovascular Pharmacology. 8 (Suppl 11): S2-15. doi:10.1097/00005344-198511001-00002. PMID2439793. S2CID24617470.
Kaumann AJ, Lemoine H (October 1985). "Direct labelling of myocardial beta 1-adrenoceptors. Comparison of binding affinity of 3H-(-)-bisoprolol with its blocking potency". Naunyn-Schmiedeberg's Archives of Pharmacology. 331 (1): 27–39. doi:10.1007/bf00498849. PMID2866449. S2CID22328991.
Smith C, Teitler M (April 1999). "Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors". Cardiovascular Drugs and Therapy. 13 (2): 123–126. doi:10.1023/A:1007784109255. PMID10372227. S2CID12639448.
Wellstein A, Palm D, Belz GG (1986). "Affinity and selectivity of beta-adrenoceptor antagonists in vitro". Journal of Cardiovascular Pharmacology. 8 (Suppl 11): S36 –S40. doi:10.1097/00005344-198511001-00006. PMID2439796. S2CID30987576.
Nuttall SL, Routledge HC, Kendall MJ (June 2003). "A comparison of the beta1-selectivity of three beta1-selective beta-blockers". Journal of Clinical Pharmacy and Therapeutics. 28 (3): 179–186. doi:10.1046/j.1365-2710.2003.00477.x. PMID12795776. S2CID58760796.
Kirch W, Rose I, Demers HG, Leopold G, Pabst J, Ohnhaus EE (August 1987). "Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease". Clinical Pharmacokinetics. 13 (2): 110–117. doi:10.2165/00003088-198713020-00003. PMID2887325. S2CID25105692.
Cvan Trobec K, Grabnar I, Kerec Kos M, Vovk T, Trontelj J, Anker SD, et al. (July 2016). "Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study". European Journal of Clinical Pharmacology. 72 (7): 813–822. doi:10.1007/s00228-016-2041-1. PMID26996442. S2CID14146663.